Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.42 |
| ▸ | PRKCG | P05129 | 4/20 | 0.42 |
| ▸ | PRKCB | P05771 | 4/20 | 0.42 |
| ▸ | PRKCA | P17252 | 4/20 | 0.42 |
| ▸ | PRKCH | P24723 | 4/20 | 0.42 |
| ▸ | PRKCI | P41743 | 4/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.42 |
| ▸ | PRKACG | P22612 | 3/20 | 0.42 |
| ▸ | PRKACB | P22694 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002842 | 1.00 | TNF (0.46) | TNFCYP3A4PRKD3PRKCGPRKCB | |
| SCHEMBL29546384 | 0.86 | CYP3A4 (0.56) | CYP3A4PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL115053 | 0.86 | CYP3A4 (0.56) | CYP3A4PRKD3PRKCGPRKCBPRKCA | |
| Hydrochloric Acid SCHEMBL987360 | 0.84 | LMNA (0.57) | CYP3A4PRKD3PRKCGPRKCBPRKCA | |
| Hydrochloric Acid SCHEMBL29469852 | 0.84 | LMNA (0.57) | CYP3A4PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL11983469 | 0.82 | TNF (0.46) | TNFCYP3A4PRKD3PRKCGPRKCB | |
| SCHEMBL18019196 | 0.82 | CA2 (0.61) | TNFCYP3A4PRKD3PRKCGPRKCB | |
| SCHEMBL26422606 | 0.82 | TNF (0.46) | TNFCYP3A4PRKD3PRKCGPRKCB | |
| Hydrochloric Acid SCHEMBL27788261 | 0.81 | TNF (0.45) | TNFCYP3A4PRKD3PRKCGPRKCB | |
| SCHEMBL28397978 | 0.78 | TNF (0.42) | TNFCYP3A4PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1467727-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| WO-2003059341-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
| US-4857301-A | ANTIALLERGENS | SCHERING CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | TNF 4084/4885CYP3A4 2475/4885PRKD3 782/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | TNF 4084/4885CYP3A4 2475/4885PRKD3 782/4885 |
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | TNF 2917/4885CYP3A4 50/4885PRKD3 4201/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TNF 4696/4885CYP3A4 329/4885PRKD3 2321/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | TNF 2915/4885CYP3A4 50/4885PRKD3 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.